BIOQUAL, Inc.
BIOQUAL provides preclinical research services supporting infectious disease, oncology and immunogenicity programs. Services include in vivo studies in small and large animals (including non-human primates), in vitro assay development and execution, BSL-3 biocontainment operations, imaging, custom animal-model development, and IND‑enabling toxicology and PK/PD studies. Facilities are AAALAC‑accredited and registered with relevant U.S. oversight bodies.
Industries
N/A
Nr. of Employees
small (1-50)
BIOQUAL, Inc.
Services
End‑to‑end in vivo studies in small and large animals including study design, execution, dosing (multiple routes), and data collection for vaccine and therapeutic development.
Cell‑based assays, immunoassays, viral‑load testing, cytotoxicity/toxicity assays and custom assay development for preclinical programs.
Access to BSL‑3 facilities and personnel qualified to conduct research on high‑risk pathogens under select‑agent standards.
Design and creation of reproducible, translational animal models including transgenic, knockout, humanized and disease‑specific models.
Toxicology, pharmacokinetics, safety studies and regulatory documentation to support IND submissions.
Imaging to assess mechanism of action, biodistribution and therapeutic efficacy in preclinical studies.
End‑to‑end in vivo studies in small and large animals including study design, execution, dosing (multiple routes), and data collection for vaccine and therapeutic development.
Cell‑based assays, immunoassays, viral‑load testing, cytotoxicity/toxicity assays and custom assay development for preclinical programs.
Access to BSL‑3 facilities and personnel qualified to conduct research on high‑risk pathogens under select‑agent standards.
Design and creation of reproducible, translational animal models including transgenic, knockout, humanized and disease‑specific models.
Toxicology, pharmacokinetics, safety studies and regulatory documentation to support IND submissions.
Imaging to assess mechanism of action, biodistribution and therapeutic efficacy in preclinical studies.
Expertise Areas
- Preclinical study design and execution
- Animal model development (small and large animals, NHP)
- Virology and vaccine testing
- Immunogenicity and immune profiling
Key Technologies
- BSL‑3 biocontainment
- Non‑human primate models
- Transgenic/knockout/humanized and xenograft models
- qRT‑PCR / RT‑PCR
News & Updates
Company press release published October 21, 2025 (press release PDF archived on site).
Interview with the company's President and Chief Scientific Officer describing strategic vision (published August 5, 2025).
Announcement of a collaborative preclinical research publication on an intranasal vaccine (February 7, 2025).
Collection of peer‑reviewed publications demonstrating preclinical study involvement across viral, bacterial and parasitic pathogens.
269 unique clients, 135 recurring clients, and 1,485 studies completed in the last five years (site statistics).
Recognition for clinical veterinary care awarded to a staff veterinarian, highlighting contributions to veterinary care and training.
Company press release published October 21, 2025 (press release PDF archived on site).
Interview with the company's President and Chief Scientific Officer describing strategic vision (published August 5, 2025).
Announcement of a collaborative preclinical research publication on an intranasal vaccine (February 7, 2025).
Collection of peer‑reviewed publications demonstrating preclinical study involvement across viral, bacterial and parasitic pathogens.
269 unique clients, 135 recurring clients, and 1,485 studies completed in the last five years (site statistics).
Recognition for clinical veterinary care awarded to a staff veterinarian, highlighting contributions to veterinary care and training.